Total: $173.18M | ||||
Company (Symbol)# |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised (M) |
Investors; Placement Agents; Details (Date)@ |
| | ||||
Allos Therapeutics Inc. (ALTH) |
Private placement of stock and warrants |
5.17S and 1.7W |
$12 |
Allos sold about 5.17M shares at $2.32 each, and issued 1.7M warrants that can be exercised until November 2007 at $3.14 per share; SG Cowen Securities Corp. was placement agent (11/20) |
|
||||
Aradigm Corp. (ARDM) |
Private placement of stock |
7.5S |
$13.5 |
Aradigm sold about 7.5M shares at $1.80 each, a discount of about 16%; SG Cowen Securities Corp. was placement agent for the deal, which included many of the investors that took part in a May 2003 financing (11/10) |
|
||||
Avanir Pharmaceuticals Inc. (AMEX:AVN) |
Private placement of stock and warrants |
5.38S and 3.23W |
$8 |
Avanir entered agreements to raise $8M by selling about 5.38M shares at $1.49 each and warrants to purchase up to 3.23M shares at $1.75; Rodman & Renshaw was placement agent (11/26) |
|
||||
Cepheid Inc. (CPHD) |
Private placement of stock |
0.556S |
$2 |
The institutional investors that purchased $10M in stock in August exercised an option on another 555,556 additional shares, bringing in another $2M; UBS Securities was financial adviser (11/10) |
|
||||
ConjuChem Inc. (Canada; TSE:CJC) |
Bought-deal financing |
6S |
C$24.9 |
ConjuChem raised the money in a bought-deal financing; the total includes the exercise of the overallotment option y Orion Securities Inc., Sprott Securities Inc. and BMO Nesbitt Burns Inc. (11/3) |
|
||||
Cytogen Corp. (CYTO) |
Private placement of stock |
1.86S |
$20.5 |
Cytogen sold the shares at $11 each to institutional investors under an effective shelf registration statement (11/7) |
|
||||
Enhance Biotech Inc. (OTC BB:EBOI) |
Private placement of stock and warrants |
ND |
$2 |
Details on the financing were not disclosed, although Enhance said it could get another $2M if it meets development milestones (11/3) |
|
||||
EntreMed Inc. (ENMD) |
Private placement of stock and warrants |
5.25S and 0.79W |
$22.3 |
EntreMed placed the shares and warrants with undisclosed institutional investors; the shares were priced at $4.25 and the warrants are exer- cisable at $5 per share; Rodman & Renshaw was placement agent (11/3) |
|
||||
Genaera Corp. (GENR) |
Registered direct offering |
2.05S |
$8.5 |
Genaera accepted subscriptions from institutional investors in a direct offering of shares priced at $4.15 each, the Nov. 10 closing price; Fortis Securities Inc. was placement agent (11/11) |
|
||||
Hemosol Inc. (Canada; HMSL) |
Sale of special warrants |
7.84W |
$5.88 |
Hemosol sold the warrants at $0.75 apiece; each special warrant entitles the holder to one common share and one-half of a warrant that in full can be exercised for one share at 90 cents for three years (11/28) |
|
||||
Inflazyme Pharmaceuticals Inc. (Canada; TSE:IZP) |
Bought-deal financing |
13.65S |
C$15 |
Inflazyme sold 13.65M shares at C$1.10 per share; underwriters Orion Securities Inc. and RBC Capital Markets have an option to purchase up to 2.05M additional shares to cover overallotments (11/25) |
|
||||
InSite Vision Inc. (AMEX:ISV) |
Assumption of redeemable debentures |
N/A |
$0.5 |
InSite received the second tranche of a $1M interim funding from an institutional investor, the first part of which was received in September; J.P. Turner & Co. Ltd. was financial representative (11/12) |
|
||||
Introgen Therapeutics Inc. (INGN) |
Private placement of stock |
2.86S |
$20 |
Introgen sold the shares at $7 each from a registration statement for a sale of up to $100M in stock; SG Cowen Securities Corp. was placement agent (11/26) |
|
||||
Keryx Biopharmaceuticals Inc. (KERX) |
Private placement of stock and warrants |
3.5S and 0.7W |
$15 |
Keryx sold 3.5M shares at $4.25 each along with about 700,000 five-year warrants exercisable at $6 per share; Rodman & Renshaw was placement agent (11/18) |
|
||||
Manhattan Pharmaceuticals Inc. (OTC BB:MHHT) |
Private placement of convertible preferred stock |
1S |
$10 |
Manhattan sold 1M shares of Series A convertible preferred stock at $10 each; the stock can be converted into common shares at $1.10 per share; the deal was completed by Maxim Group LLC and Paramount Capital Inc. (11/10) |
|
||||
Neoprobe Corp. (OTC BB:NEOP) |
Private placement of stock and warrants |
12.2S and 6.1W |
$2.8 |
Neoprobe sold 12.2M shares at 23 cents per share and issued five-year Series R warrants to purchase 6.1M shares at 28 cents each; institutional investors and high-net-worth individuals participated (11/17) |
|
||||
| | ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
N/A = Not available, applicable or reported; ND = Not disclosed. | ||||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
